About Arena Therapeutics

Arena Therapeutics is a start-up focused on advancing Deep Brain Stimulation (DBS) for the treatment of patients recently diagnosed with Parkinson's disease. Each year in the U.S. approximately 60,000 people are diagnosed with Parkinson's disease and approximately 1.5 million people suffer from the disease. Current treatment including DBS are only symptomatic.

David Charles, M.D. is Professor and Vice-Chair of Neurology and Medical Director of TeleHealth at Vanderbilt University Medical Center. The team generated clinical data from a randomized, controlled feasibility trial suggesting future research in a multicenter clinical trial to determine if DBS is safe and efficacious and whether early intervention could slow the progression of symptoms (Charles et al., 2014; Hacker et al., 2015; Hacker et al., 2016). Dr. Charles is the company's principal founder. 

contact arena therapeutics ▸

chief executive officer

Todd Langevin

Mr. Langevin has more than 25 years in medical devices, the majority of which at Medtronic, most recently as Vice President and General Manager of Medtronic's DBS business. He earned a BS in Biology from the University of Minnesota and an MBA from the University of St Thomas, St. Paul, MN.

CHAIRMAN

David Charles, M.D.

Dr. Charles is Professor and Vice-Chair of Neurology and Medical Director of TeleHealth at Vanderbilt University Medical Center. Dr. Charles graduated from Vanderbilt School of Engineering and earned his MD from Vanderbilt School of Medicine. Dr. Charles conducted Parkinson’s disease research in France as a Fulbright Senior Scholar.

director, research and development

Mallory Hacker, Ph.D., M.S.C.I.

Dr. Hacker is Assistant Professor of Neurology at Vanderbilt University Medical Center. She graduated from the University of Tennessee at Chattanooga with a degree in Chemistry, earned her PhD from Vanderbilt University in Cell and Developmental Biology, and received a graduate degree in clinical trials from Vanderbilt University School of Medicine. She has over seven years' experience designing and leading clinical trials. She also has expertise in FDA regulatory approval of medical devices for use in clinical investigation. Dr. Hacker received the 2019 Kumar New Investigator Award from the North American Neuromodulation Society and is a member of the Movement Disorders Society, the American Neurological Association, the American Academy of Neurology, the North American Neuromodulation Society, and the Society for Clinical Trials.

CHIEF OPERATING OFFICER

Tim DeLapp

Mr. DeLapp is a proven versatile business leader with over 37 years in executive and managerial roles in the medtech industry. He spent 30 years at Medtronic, which included global leadership roles in its DBS business. His career experience includes general business management, global market development, and new therapy development. Tim currently leads an executive management advisory firm serving the medtech industry. He earned a BS in Business majoring in Economics from the University of Missouri-Columbia and an MBA from the University of St. Thomas, St. Paul, MN.